Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the twelve analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $14.56.

Several research analysts recently weighed in on CATX shares. Bank of America cut Perspective Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday. HC Wainwright initiated coverage on shares of Perspective Therapeutics in a report on Thursday. They issued a "buy" rating and a $10.00 price objective for the company. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Finally, Scotiabank initiated coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CATX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Perspective Therapeutics by 19.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company's stock valued at $224,000 after purchasing an additional 11,472 shares during the period. Velan Capital Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at about $1,595,000. Squarepoint Ops LLC acquired a new position in Perspective Therapeutics during the fourth quarter worth $626,000. Wexford Capital LP acquired a new position in Perspective Therapeutics in the 4th quarter valued at about $64,000. Finally, Two Sigma Advisers LP acquired a new stake in Perspective Therapeutics during the 4th quarter worth approximately $484,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Perspective Therapeutics Stock Down 1.3 %

Shares of CATX stock traded down $0.04 during trading hours on Monday, hitting $2.63. The company's stock had a trading volume of 357,712 shares, compared to its average volume of 806,331. The company has a 50 day moving average of $3.17 and a 200 day moving average of $7.44. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.